Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate

Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate

The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Neumann Heike, Formell Michael, Winter Gabriele, Benke Klaus
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Neumann Heike
Formell Michael
Winter Gabriele
Benke Klaus
description The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anemia, chronic renal disorders and renal insufficiency.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US9827198B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US9827198B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US9827198B23</originalsourceid><addsrcrecordid>eNqNjj8LwjAUxLs4iPodMlboG1L_tauidBTUSaSENm0fJH0hSYe6-NUN0g_gcscdv4ObR59rJ6wWlRw8VkKxmpxoJWvIascq0saiw75ljmocNHB47iHWZE1HCnvYwqjWZrSosZ7iK2jMC-BJmmzAWxRvUmEYQAh1gH_FDkgJL5fRrBHKydXki4hdzvdTAdJQKZ0Jz3rpy8ctz9IDz7NjuvkD-QKcn0UA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate</title><source>esp@cenet</source><creator>Neumann Heike ; Formell Michael ; Winter Gabriele ; Benke Klaus</creator><creatorcontrib>Neumann Heike ; Formell Michael ; Winter Gabriele ; Benke Klaus</creatorcontrib><description>The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anemia, chronic renal disorders and renal insufficiency.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20171128&amp;DB=EPODOC&amp;CC=US&amp;NR=9827198B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20171128&amp;DB=EPODOC&amp;CC=US&amp;NR=9827198B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Neumann Heike</creatorcontrib><creatorcontrib>Formell Michael</creatorcontrib><creatorcontrib>Winter Gabriele</creatorcontrib><creatorcontrib>Benke Klaus</creatorcontrib><title>Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate</title><description>The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anemia, chronic renal disorders and renal insufficiency.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjj8LwjAUxLs4iPodMlboG1L_tauidBTUSaSENm0fJH0hSYe6-NUN0g_gcscdv4ObR59rJ6wWlRw8VkKxmpxoJWvIascq0saiw75ljmocNHB47iHWZE1HCnvYwqjWZrSosZ7iK2jMC-BJmmzAWxRvUmEYQAh1gH_FDkgJL5fRrBHKydXki4hdzvdTAdJQKZ0Jz3rpy8ctz9IDz7NjuvkD-QKcn0UA</recordid><startdate>20171128</startdate><enddate>20171128</enddate><creator>Neumann Heike</creator><creator>Formell Michael</creator><creator>Winter Gabriele</creator><creator>Benke Klaus</creator><scope>EVB</scope></search><sort><creationdate>20171128</creationdate><title>Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate</title><author>Neumann Heike ; Formell Michael ; Winter Gabriele ; Benke Klaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US9827198B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2017</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Neumann Heike</creatorcontrib><creatorcontrib>Formell Michael</creatorcontrib><creatorcontrib>Winter Gabriele</creatorcontrib><creatorcontrib>Benke Klaus</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Neumann Heike</au><au>Formell Michael</au><au>Winter Gabriele</au><au>Benke Klaus</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate</title><date>2017-11-28</date><risdate>2017</risdate><abstract>The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anemia, chronic renal disorders and renal insufficiency.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US9827198B2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A38%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Neumann%20Heike&rft.date=2017-11-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS9827198B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true